Compare GSK plc (GSK) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vital Farms Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Vital Farms Inc trades at $9.33 (market cap $405.27M). The key difference: GSK plc is far larger — about 226.7× Vital Farms Inc's market cap, and GSK plc pays a 3.9% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vital Farms Inc for 14 Days on average.
| GSK | VITL | |
|---|---|---|
Market Cap | $91.88B | $405.27M |
Volume | 7,730,529 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $43.68 |
52-Week Low | $43.24 | $8.28 |
Typical Hold Time | 93 Days | 14 Days |
Enterprise Value | $111.88B | $492.28M |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Vital Farms (VITL) trades at $9.33, showing modest daily gains but facing significant fundamental challenges. The company reported declining revenue and profitability in 2026, with net income margin collapsing to 0.02% from 8.72% in 2025. Technical indicators show bearish momentum, while analyst sentiment remains cautiously optimistic with a $13.11 consensus target. Recent news highlights strategic review possibilities and institutional accumulation despite operational headwinds.
The outlook remains challenging with pricing pressure and supply issues affecting margins, though strategic options exploration provides potential upside. Investment opportunity exists if operational improvements materialize, but risks include sustained margin compression and execution challenges in a competitive egg market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
